TORONTO (August 16, 2010) – MaRS Innovation (MI) is pleased to announce that translational funding to support product development for early-stage technologies from its members has been successfully deployed from federal and provincial sources. At the federal level, three of MI’s commercialization projects have recently received notification of funding from the Canadian Institutes of Health Research (CIHR) Proof of Principle (PoP) program, amounting to approximately $470,000.
Moreover, MI has successfully deployed about $1 million in proof of principle funding received from the Ontario Ministry of Research ...
MaRS Innovation (MI) has signed a co-funding agreement with the Johnson & Johnson Corporate Office of Science and Technology to capitalize and accelerate the use of Toronto-based life sciences technologies during the early stages of pharmaceutical and medical device development.
The Translational Innovation Partnership Program (TIPP) is the first co-funding agreement of its kind for MI. (more…)
TORONTO (March 23, 2010) — MaRS Innovation and Sunnybrook Health Sciences Centre have entered into their first set of agreements to collaboratively commercialize a novel therapeutic technology and three advances in medical imaging. These four technologies will impact diagnosis and care for epidemic chronic illnesses and have clear and broad commercial potential. MI will shepherd these opportunities through the next stages of the commercialization process.
“We are coming out of the gate vigorously in identifying this group of Sunnybrook technologies as commercialization ...
TORONTO (March 2, 2010) – MaRS Innovation is delighted to announce that two of its commercialization projects – notably an umbilical cord stem cell technology from Mount Sinai Hospital and nicotine addiction therapy from the Centre for Addiction and Mental Health (CAMH) - have received Canadian Institutes of Health Research (CIHR) Proof of Principle (PoP) funding.
This funding – each grant is valued at $150,000 – is third party validation of MaRS Innovation’s approach to commercializing its members’ discoveries. The CIHR performs rigorous due diligence and ...
TORONTO, ON and VANCOUVER, BC (November 30, 2009) - MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries.
“We are excited about our partnership with the CDRD as it provides an opportunity for the two organizations to augment each other’s strengths, and leverage resources to generate attractive packages for potential partners, thereby supporting both of our organizations’ ...
TORONTO (November 19, 2009) – In the drive to improve early detection and treatment of cancer, a pair of Toronto scientists has developed a unique technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms.
While contrast agents are routinely injected into patients to enhance the quality of medical images, different agents are currently required for various imaging modes (e.g. MRI, CT, PET) each with inherent strengths and limitations. By combining more than one contrast agent into a nano-particle ...
TORONTO (June 30, 2009) – MaRS Innovation (MI) and the University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.
“There are 300 million diabetics worldwide, of which some 15 per cent develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some ...
TORONTO (June 29, 2009) – MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are pleased to announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.
“With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialization opportunity,” said Dr. Raphael (Rafi) Hofstein, President ...